Frédéric Stauffer

2.2k citations

26 papers · 1.9k · 1 hit paper · h-index 16

Impact in

Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related gene regulation
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
Genetics top 10%
- Glioma Diagnosis and Treatment

Papers in

Hematology 6
- Acute Myeloid Leukemia Research 5
Molecular Biology 16
- PI3K/AKT/mTOR signaling in cancer 9
- Protein Degradation and Inhibitors 3
- Cancer-related gene regulation 3

Co-authors: Sauveur-Michel Maira (7 shared papers)Christian Schnell (5 shared papers)Pascal Furet (8 shared papers)Carlos Garcia-Echeverria (2 shared papers)Marjo Simonen (1 shared paper)Saskia M. Brachmann (1 shared paper)Leon O. Murphy (1 shared paper)Alain De Pover (1 shared paper)
Journals: ACS Medicinal Chemistry Letters (5 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)Cancer Research (2 papers)Blood (1 paper)Molecular Cancer Therapeutics (1 paper)
Partner nations: Switzerland United States

In The Last Decade

Frédéric Stauffer

26 papers receiving 1.9k citations

Frédéric Stauffer's Hit Papers

align trajectories log scale

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity 2008 · 1k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2008 Molecular Cancer Therapeutics

Peers

Countries citing papers authored by Frédéric Stauffer

Since Specialization

Citations

This map shows the geographic impact of Frédéric Stauffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Stauffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Stauffer more than expected).

Fields of papers citing papers by Frédéric Stauffer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Stauffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Stauffer. The network helps show where Frédéric Stauffer may publish in the future.

Co-authors

The 25 scholars most cited alongside Frédéric Stauffer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frédéric Stauffer Line = papers co-authored together Frédéric Stauffer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Molecular Cancer Therapeutics ·Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Pascal Furet, Christian Schnell, Christine M. Fritsch, Saskia M. Brachmann, Patrick Chêne Hit paper breakdown →	2008	1029
2	Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging Cancer Research ·Christian Schnell, Frédéric Stauffer, Peter Roland ALLEGRINI, Terence O’Reilly, Paul M.J. McSheehy, Celine Dartois, Michael Stumm, Robert M. Cozens	2008	150
3	PI3K inhibitors for cancer treatment: where do we stand? Biochemical Society Transactions ·Sauveur-Michel Maira, Frédéric Stauffer, Christian Schnell, Carlos Garcı́a-Echeverrı́a	2009	97
4	Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors Molecular Cancer Research ·Romina Marone, Dominik Erhart, Ann C. Mertz, Thomas Bohnacker, Christian Schnell, Vladimir Cmiljanović, Frédéric Stauffer, Carlos Garcı́a-Echeverrı́a	2009	94
5	Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway Bioorganic & Medicinal Chemistry Letters ·Frédéric Stauffer, Sauveur-Michel Maira, Pascal Furet, Carlos Garcı́a-Echeverrı́a	2008	81
6	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors ACS Medicinal Chemistry Letters ·Klemens Hoegenauer, Nicolas Soldermann, Frédéric Stauffer, Pascal Furet, Nadège Graveleau, Alexander B. Smith, Christina Hebach, Gregory J. Hollingworth	2016	55
7	Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach ACS Medicinal Chemistry Letters ·Chao Chen, Hugh Y. H. Zhu, Frédéric Stauffer, Giorgio Caravatti, Susanne Vollmer, Rainer Machauer, Philipp Holzer, Henrik Möbitz	2016	53
8	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach ACS Medicinal Chemistry Letters ·Henrik Möbitz, Rainer Machauer, Philipp Holzer, Andrea Vaupel, Frédéric Stauffer, Christian Ragot, Giorgio Caravatti, Clemens Scheufler	2017	44
9	Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts Blood ·Florian Perner, Jayant Y. Gadrey, Yijun Xiong, Charlie Hatton, Benjamin K. Eschle, Andreas Weiss, Frédéric Stauffer, Christoph Gaul	2020	44
10	Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket ACS Medicinal Chemistry Letters ·Clemens Scheufler, Henrik Möbitz, Christoph Gaul, Christian Ragot, Celine Be, César Fernández Fernández, Kim S. Beyer, Ralph Tiedt	2016	41
11	New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse ACS Medicinal Chemistry Letters ·Frédéric Stauffer, Andreas Weiss, Clemens Scheufler, Henrik Möbitz, Christian Ragot, Kim S. Beyer, Keith Calkins, Daniel Alexander Guthy	2019	35
12	Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065 Bioorganic & Medicinal Chemistry ·Jay P. Parrish, David B. Kastrinsky, Frédéric Stauffer, Michael P. Hedrick, Inkyu Hwang, Dale L. Boger	2003	31
13	Calamitic liquid crystals containing metal–metal bonds: design of mesomorphic materials based on the Ru2(CO)4(μ-η2-O2CR)2L2 sawhorse unit † Journal of the Chemical Society Dalton Transactions ·Robert Deschenaux, Bertrand Donnio, G. Rheinwald, Frédéric Stauffer, Georg Süß‐Fink, Jörg Velker	1997	28
14	Discovery of Novel Anticancer Therapeutics Targeting the Pi3K/Akt/Mtor Pathway Future Medicinal Chemistry ·Sauveur-Michel Maira, Pascal Furet, Frédéric Stauffer	2009	26
15	A General Strategy for Targeting Drugs to Bone Angewandte Chemie International Edition ·Wolfgang Jahnke, Guido Bold, Andreas L. Marzinzik, Silvio Ofner, Xavier Pellé, Simona Cotesta, Emmanuelle Bourgier, Sylvie Lehmann	2015	25
16	Discovery of Novel Allosteric Non‐Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding ChemMedChem ·Andreas L. Marzinzik, René Amstutz, Guido Bold, Emmanuelle Bourgier, Simona Cotesta, Joseph Fraser Glickman, Marjo Götte, Christelle Henry	2015	25
17	Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors Bioorganic & Medicinal Chemistry Letters ·Frédéric Stauffer, Sandra W. Cowan‐Jacob, Clemens Scheufler, Pascal Furet	2016	16
18	Substituent effects within the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065 Bioorganic & Medicinal Chemistry Letters ·Dale L. Boger, Frédéric Stauffer, Michael P. Hedrick	2001	13
19	New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series Bioorganic & Medicinal Chemistry Letters ·Frédéric Stauffer, Pascal Furet, Andreas Floersheimer, Marc Lang	2012	13
20	DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway Oncotarget ·Caroline Dafflon, Swann Gaulis, Louise Barys, Karen Kapur, Vanessa Cornacchione, Lina Schukur, Sebastian Bergling, Elisabetta Traggiai	2020	12

About Frédéric Stauffer

Frédéric Stauffer is a scholar working on Hematology, Molecular Biology, Organic Chemistry, Computational Theory and Mathematics and Endocrinology, Diabetes and Metabolism, having authored 26 papers that have together received 1.9k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (9 papers), Acute Myeloid Leukemia Research (5 papers), Computational Drug Discovery Methods (5 papers), Protein Degradation and Inhibitors (3 papers), Cancer-related gene regulation (3 papers), Synthesis and biological activity (3 papers), Bone health and treatments (2 papers) and Synthesis and pharmacology of benzodiazepine derivatives (2 papers). The work is most often cited by research in Molecular Biology (1.3k citations), Genetics (79 citations), Hematology (120 citations), Computational Theory and Mathematics (111 citations) and Organic Chemistry (210 citations). Frédéric Stauffer has collaborated with scholars based in Switzerland and United States. Frequent co-authors include Sauveur-Michel Maira, Christian Schnell, Pascal Furet, Carlos Garcia-Echeverria, Marjo Simonen, Saskia M. Brachmann, Leon O. Murphy, Alain De Pover, William R. Sellers and Doriano Fabbro. Their work appears in journals such as ACS Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry Letters, Cancer Research, Blood and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Frédéric Stauffer

Impact in

Papers in i

In The Last Decade

Frédéric Stauffer

Frédéric Stauffer's Hit Papers

Peers

Countries citing papers authored by Frédéric Stauffer

Fields of papers citing papers by Frédéric Stauffer

All Works

About Frédéric Stauffer

Explore authors with similar magnitude of impact

Papers in